International Journal of Endocrinology and Metabolism

Published by: Kowsar

Biochemical Assessment: Findings from 20 Years of the Tehran Lipid and Glucose Study

Mehdi Hedayati 1 , Maryam Sadat Daneshpour 1 , Maryam Zarkesh 1 , Marjan Zarif Yeganeh 1 , Sara Sheikholeslami 1 , Bita Faam 1 and Fereidoun Azizi 2 , *
Authors Information
1 Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Article information
  • International Journal of Endocrinology and Metabolism: October 2018, 16 (4 (Suppl)); e84783
  • Published Online: October 16, 2018
  • Article Type: Review Article
  • Received: September 1, 2018
  • Revised: October 2, 2018
  • Accepted: October 7, 2018
  • DOI: 10.5812/ijem.84783

To Cite: Hedayati M, Daneshpour M S , Zarkesh M , Zarif Yeganeh M, Sheikholeslami S, et al. Biochemical Assessment: Findings from 20 Years of the Tehran Lipid and Glucose Study, Int J Endocrinol Metab. 2018 ; 16(4 (Suppl)):e84783. doi: 10.5812/ijem.84783.

Abstract
Copyright © 2018, International Journal of Endocrinology and Metabolism. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Methods
3. Results
4. Discussion
Acknowledgements
Footnotes
References
  • 1. Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014;2014:943162. doi: 10.1155/2014/943162. [PubMed: 24711954]. [PubMed Central: PMC3966331].
  • 2. Tohidi M, Hadaegh F, Harati H, Azizi F. C-reactive protein in risk prediction of cardiovascular outcomes: Tehran lipid and glucose Study. Int J Cardiol. 2009;132(3):369-74. doi: 10.1016/j.ijcard.2007.11.085. [PubMed: 18242731].
  • 3. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: Evidence on causality from a meta-analysis. BMJ. 2002;325(7374):1202. doi: 10.1136/bmj.325.7374.1202. [PubMed: 12446535]. [PubMed Central: PMC135491].
  • 4. Agoston-Coldea L, Mocan T, Dobie L, Marginean A, Lupu S. The association between homocysteine level and metabolic syndrome in patients of prior myocardial infarction. Rom J Intern Med. 2010;48(2):151-8. [PubMed: 21428179].
  • 5. Coelho M, Oliveira T, Fernandes R. Biochemistry of adipose tissue: An endocrine organ. Arch Med Sci. 2013;9(2):191-200. doi: 10.5114/aoms.2013.33181. [PubMed: 23671428]. [PubMed Central: PMC3648822].
  • 6. Azizi F, Ghanbarian A, Momenan AA, Hadaegh F, Mirmiran P, Hedayati M, et al. Prevention of non-communicable disease in a population in nutrition transition: Tehran lipid and glucose study phase II. Trials. 2009;10:5. doi: 10.1186/1745-6215-10-5. [PubMed: 19166627]. [PubMed Central: PMC2656492].
  • 7. de Ferranti S, Rifai N. C-reactive protein and cardiovascular disease: A review of risk prediction and interventions. Clin Chim Acta. 2002;317(1-2):1-15. doi: 10.1016/S0009-8981(01)00797-5. [PubMed: 11814453].
  • 8. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003;107(3):391-7. doi: 10.1161/01.CIR.0000055014.62083.05. [PubMed: 12551861].
  • 9. Heald AH, Anderson SG, Ivison F, Laing I, Gibson JM, Cruickshank K. C-reactive protein and the insulin-like growth factor (IGF)-system in relation to risk of cardiovascular disease in different ethnic groups. Atherosclerosis. 2003;170(1):79-86. doi: 10.1016/S0021-9150(03)00235-1. [PubMed: 12957685].
  • 10. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282(22):2131-5. doi: 10.1001/jama.282.22.2131. [PubMed: 10591334].
  • 11. Hosseinzadeh-Attar MJ, Golpaie A, Foroughi M, Hosseinpanah F, Zahediasl S, Azizi F. The relationship between visfatin and serum concentrations of C-reactive protein, interleukin 6 in patients with metabolic syndrome. J Endocrinol Invest. 2016;39(8):917-22. doi: 10.1007/s40618-016-0457-1. [PubMed: 27023106].
  • 12. Zarkesh M, Faam B, Daneshpour MS, Azizi F, Hedayati M. The relationship between metabolic syndrome, cardiometabolic risk factors and inflammatory markers in a Tehranian population: The Tehran lipid and glucose study. Intern Med. 2012;51(24):3329-35. doi: 10.2169/internalmedicine.51.8475. [PubMed: 23257516].
  • 13. Zarkesh M, Faam B, Daneshpour MS, Azizi F, Hedayati M. [Association between metabolic syndrome and hs-CRP, Hcy, and IL-6 levels]. Iran J Diabet Metabol. 2013;12(6):564-73. Persian.
  • 14. Faam B, Zarkesh M, Daneshpour MS, Azizi F, Hedayati M. The association between inflammatory markers and obesity-related factors in Tehranian adults: Tehran lipid and glucose study. Iran J Basic Med Sci. 2014;17(8):577-82. [PubMed: 25422750]. [PubMed Central: PMC4240791].
  • 15. Faam B, Zarkesh M, Daneshpour MS, Azizi F, Hedayati M. [Association between abdominal obesity and HS-CRP, IL-6 and HCY in Tehranian adults: TLGS]. Iran J Diabet Metabol. 2014;13(2):163-71. Persian.
  • 16. Ebrahim M, Tohidi M, Hadaegh F, Azizi F. [Role of C-reactive protein in prediction of type 2 diabetes: Tehran lipid and glucose study]. Iran J Endocrinol Metabol. 2008;10(1):11-6. Persian.
  • 17. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10). a016295. doi: 10.1101/cshperspect.a016295. [PubMed: 25190079]. [PubMed Central: PMC4176007].
  • 18. Hsu DC, Ma YF, Hur S, Li D, Rupert A, Scherzer R, et al. Plasma IL-6 levels are independently associated with atherosclerosis and mortality in HIV-infected individuals on suppressive antiretroviral therapy. AIDS. 2016;30(13):2065-74. doi: 10.1097/QAD.0000000000001149. [PubMed: 27177313]. [PubMed Central: PMC5586221].
  • 19. Zakynthinos E, Pappa N. Inflammatory biomarkers in coronary artery disease. J Cardiol. 2009;53(3):317-33. doi: 10.1016/j.jjcc.2008.12.007. [PubMed: 19477372].
  • 20. Catena C, Colussi G, Nait F, Capobianco F, Sechi LA. Elevated homocysteine levels are associated with the metabolic syndrome and cardiovascular events in hypertensive patients. Am J Hypertens. 2015;28(7):943-50. doi: 10.1093/ajh/hpu248. [PubMed: 25498997].
  • 21. Stelzer I, Zelzer S, Raggam RB, Pruller F, Truschnig-Wilders M, Meinitzer A, et al. Link between leptin and interleukin-6 levels in the initial phase of obesity related inflammation. Transl Res. 2012;159(2):118-24. doi: 10.1016/j.trsl.2011.10.001. [PubMed: 22243796].
  • 22. Vaya A, Rivera L, Hernandez-Mijares A, de la Fuente M, Sola E, Romagnoli M, et al. Homocysteine levels in morbidly obese patients: Its association with waist circumference and insulin resistance. Clin Hemorheol Microcirc. 2012;52(1):49-56. doi: 10.3233/CH-2012-1544. [PubMed: 22460264].
  • 23. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: A case-control study. Lancet. 2005;366(9497):1640-9. doi: 10.1016/S0140-6736(05)67663-5. [PubMed: 16271645].
  • 24. Liu J, Fox CS, Hickson D, Bidulescu A, Carr JJ, Taylor HA. Fatty liver, abdominal visceral fat, and cardiometabolic risk factors: The Jackson heart study. Arterioscler Thromb Vasc Biol. 2011;31(11):2715-22. doi: 10.1161/ATVBAHA.111.234062. [PubMed: 21885852]. [PubMed Central: PMC3228266].
  • 25. Kazemi-Saleh D, Koosha P, Sadeghi M, Sarrafzadegan N, Karbasi-Afshar R, Boshtam M, et al. Predictive role of adiponectin and high-sensitivity C-reactive protein for prediction of cardiovascular event in an Iranian cohort Study: The Isfahan cohort study. ARYA Atheroscler. 2016;12(3):132-7. [PubMed: 27752270]. [PubMed Central: PMC5055371].
  • 26. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350(14):1387-97. doi: 10.1056/NEJMoa032804. [PubMed: 15070788].
  • 27. Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The insulin resistance atherosclerosis study. Kidney Int. 2000;58(4):1703-10. doi: 10.1046/j.1523-1755.2000.00331.x. [PubMed: 11012904].
  • 28. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (monitoring trends and determinants in cardiovascular disease) augsburg cohort study, 1984 to 1992. Circulation. 1999;99(2):237-42. doi: 10.1161/01.CIR.99.2.237. [PubMed: 9892589].
  • 29. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes. 2004;53(3):693-700. doi: 10.2337/diabetes.53.3.693. [PubMed: 14988254].
  • 30. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327-34. doi: 10.1001/jama.286.3.327. [PubMed: 11466099].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments